Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LGND
LGND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGND News
FDA Approves Filspari for Rare Kidney Disorder Treatment
6d ago
stocktwits
FDA Approves Travere and Ligand's Joint Kidney Disease Therapy Expansion
6d ago
seekingalpha
Ligand's Partner Receives FDA Approval for FSGS Treatment
6d ago
NASDAQ.COM
FILSPARI Receives FDA Approval for FSGS Treatment
6d ago
Newsfilter
Travere Therapeutics Receives FDA Approval for New Drug
6d ago
stocktwits
FDA Extends Review Period for Filspari Drug Application
Apr 10 2026
stocktwits
Ligand Pharmaceuticals Executive Exercises Stock Options
Mar 31 2026
NASDAQ.COM
Ligand Pharmaceuticals Executive Sells Stock Options for $1.03 Million
Mar 31 2026
Fool
Ligand Pharmaceuticals CFO Sells $688,000 in Stock
Mar 28 2026
Fool
BofA Initiates Coverage on Ligand Pharmaceuticals with Buy Rating
Mar 11 2026
Benzinga
LIGAND PHARMACEUTICALS INC: BOFA GLOBAL RESEARCH STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $244
Mar 11 2026
moomoo
Bank of America Initiates Buy on Ligand Pharmaceuticals with $244 Target
Mar 11 2026
seekingalpha
Latest Wall Street Rating Updates
Mar 11 2026
CNBC
Rice Hall James Increases Stake in QuidelOrtho
Mar 09 2026
Fool
Rice Hall James Increases Stake in QuidelOrtho
Mar 09 2026
NASDAQ.COM
Rice Hall James Increases Stake in Stride by 122,430 Shares
Mar 09 2026
Fool
Show More News
